Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. In a recent study, it was found ...

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...

NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

People assigned female at birth can get a rare type of cancer called Skene’s gland cancer, similar to prostate cancer. People with this type of cancer can have a range of urinary symptoms as well as ...

If you or a loved one has prostate cancer, you may be interested in learning about medicines used to treat it. One option is a medicine called Erleada (apalutamide). The FDA approved Erleada in 2018.